Does the media refer more to AGIO or IMMX?

In the previous week, Immix Biopharma had 13 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 15 mentions for Immix Biopharma and 2 mentions for Agios Pharmaceuticals. Immix Biopharma's average media sentiment score of 1.34 beat Agios Pharmaceuticals' score of 0.88 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IMMX or ANIP?

In the previous week, Immix Biopharma had 14 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 15 mentions for Immix Biopharma and 1 mentions for ANI Pharmaceuticals. Immix Biopharma's average media sentiment score of 1.34 beat ANI Pharmaceuticals' score of 0.90 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LKFT or IMMX more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Immix Biopharma N/A -73.24% -59.20%

Is IMMX or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Rapport Therapeutics N/A -24.78% -23.44%

Does the media favor IMMX or RAPP?

In the previous week, Immix Biopharma had 11 more articles in the media than Rapport Therapeutics. MarketBeat recorded 15 mentions for Immix Biopharma and 4 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.62 beat Immix Biopharma's score of 1.34 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Immix Biopharma (IMMX) Competitors

$9.91 +0.51 (+5.43%)

Closing price 04:00 PM Eastern

Extended Trading

$9.90 -0.01 (-0.14%)

As of 07:58 PM Eastern

Compare

IMMX vs. AGIO, ANIP, LKFT, BHC, and RAPP

Should you buy Immix Biopharma stock or one of its competitors? MarketBeat compares Immix Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immix Biopharma include Agios Pharmaceuticals (AGIO), ANI Pharmaceuticals (ANIP), Lakefront Biotherapeutics American Depositary Shares (LKFT), Bausch Health Cos (BHC), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry.

How does Immix Biopharma compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Immix Biopharma (NASDAQ:IMMX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Immix Biopharma has lower revenue, but higher earnings than Agios Pharmaceuticals. Immix Biopharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	39.27	-$412.78M	-$7.25	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

11.3% of Immix Biopharma shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Immix Biopharma had 13 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 15 mentions for Immix Biopharma and 2 mentions for Agios Pharmaceuticals. Immix Biopharma's average media sentiment score of 1.34 beat Agios Pharmaceuticals' score of 0.88 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals currently has a consensus price target of $40.89, suggesting a potential upside of 14.60%. Immix Biopharma has a consensus price target of $20.67, suggesting a potential upside of 108.54%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Agios Pharmaceuticals has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

Immix Biopharma has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Immix Biopharma	N/A	-73.24%	-59.20%

Summary

Immix Biopharma beats Agios Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to ANI Pharmaceuticals?

Immix Biopharma (NASDAQ:IMMX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Immix Biopharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
ANI Pharmaceuticals	$883.37M	2.14	$78.34M	$3.95	21.00

In the previous week, Immix Biopharma had 14 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 15 mentions for Immix Biopharma and 1 mentions for ANI Pharmaceuticals. Immix Biopharma's average media sentiment score of 1.34 beat ANI Pharmaceuticals' score of 0.90 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has a net margin of 9.98% compared to Immix Biopharma's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Immix Biopharma presently has a consensus target price of $20.67, suggesting a potential upside of 108.54%. ANI Pharmaceuticals has a consensus target price of $107.33, suggesting a potential upside of 29.41%. Given Immix Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immix Biopharma is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

ANI Pharmaceuticals beats Immix Biopharma on 9 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.50, indicating a potential upside of 25.65%. Immix Biopharma has a consensus target price of $20.67, indicating a potential upside of 108.54%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Immix Biopharma is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Immix Biopharma. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.52	$363.05M	-$1.41	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

In the previous week, Immix Biopharma had 12 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 15 mentions for Immix Biopharma and 3 mentions for Lakefront Biotherapeutics American Depositary Shares. Immix Biopharma's average media sentiment score of 1.34 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.61 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Immix Biopharma	N/A	-73.24%	-59.20%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Immix Biopharma beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Immix Biopharma had 15 more articles in the media than Bausch Health Cos. MarketBeat recorded 15 mentions for Immix Biopharma and 0 mentions for Bausch Health Cos. Immix Biopharma's average media sentiment score of 1.34 beat Bausch Health Cos' score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch Health Cos	Neutral
Immix Biopharma	Positive

Bausch Health Cos has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

Immix Biopharma has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Immix Biopharma's return on equity of -73.24% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Immix Biopharma	N/A	-73.24%	-59.20%

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by insiders. Comparatively, 30.3% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bausch Health Cos has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Bausch Health Cos presently has a consensus price target of $8.00, suggesting a potential upside of 67.01%. Immix Biopharma has a consensus price target of $20.67, suggesting a potential upside of 108.54%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Immix Biopharma beats Bausch Health Cos on 9 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Rapport Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

In the previous week, Immix Biopharma had 11 more articles in the media than Rapport Therapeutics. MarketBeat recorded 15 mentions for Immix Biopharma and 4 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.62 beat Immix Biopharma's score of 1.34 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immix Biopharma currently has a consensus target price of $20.67, suggesting a potential upside of 108.54%. Rapport Therapeutics has a consensus target price of $58.83, suggesting a potential upside of 51.32%. Given Immix Biopharma's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Immix Biopharma has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

11.3% of Immix Biopharma shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rapport Therapeutics' return on equity of -24.78% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Immix Biopharma has higher earnings, but lower revenue than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Rapport Therapeutics	$20M	92.98	-$111.48M	-$2.60	N/A

Summary

Rapport Therapeutics beats Immix Biopharma on 8 of the 15 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMX vs. The Competition

Export

Metric	Immix Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$511.47M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-10.77	19.75	24.92	23.97
Price / Sales	N/A	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	5.60	8.29	10.79	6.50
Net Income	-$29.44M	$23.85M	$3.56B	$336.88M
7 Day Performance	13.39%	5.21%	1.67%	-0.22%
1 Month Performance	12.87%	2.19%	0.43%	0.77%
1 Year Performance	344.39%	60.99%	32.84%	31.57%

Immix Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMX Immix Biopharma	3.6655 of 5 stars	$9.91 +5.4%	$20.67 +108.5%	+319.6%	$511.47M	N/A	N/A	9	Positive News
AGIO Agios Pharmaceuticals	2.8536 of 5 stars	$33.08 +3.9%	$40.89 +23.6%	+2.0%	$1.89B	$54.03M	N/A	390
ANIP ANI Pharmaceuticals	4.1994 of 5 stars	$80.52 -3.0%	$107.33 +33.3%	+22.9%	$1.89B	$883.37M	20.38	600
LKFT Lakefront Biotherapeutics American Depositary Shares	2.1481 of 5 stars	$28.37 +0.7%	$36.50 +28.7%	+5.5%	$1.86B	$1.26B	N/A	1,310	News Coverage
BHC Bausch Health Cos	2.7895 of 5 stars	$4.76 -4.1%	$8.00 +68.2%	-24.4%	$1.86B	$10.27B	N/A	20,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immix Biopharma (IMMX) Competitors

IMMX vs. AGIO, ANIP, LKFT, BHC, and RAPP

How does Immix Biopharma compare to Agios Pharmaceuticals?

Summary

How does Immix Biopharma compare to ANI Pharmaceuticals?

Summary

How does Immix Biopharma compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Immix Biopharma compare to Bausch Health Cos?

Summary

How does Immix Biopharma compare to Rapport Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immix Biopharma (IMMX) Competitors

IMMX vs. AGIO, ANIP, LKFT, BHC, and RAPP

How does Immix Biopharma compare to Agios Pharmaceuticals?

Which has higher earnings & valuation, AGIO or IMMX?

Do institutionals & insiders have more ownership in AGIO or IMMX?

Does the media refer more to AGIO or IMMX?

Do analysts prefer AGIO or IMMX?

Which has more risk and volatility, AGIO or IMMX?

Is AGIO or IMMX more profitable?

Summary

How does Immix Biopharma compare to ANI Pharmaceuticals?

Which has more risk & volatility, IMMX or ANIP?

Which has higher valuation & earnings, IMMX or ANIP?

Does the media favor IMMX or ANIP?

Is IMMX or ANIP more profitable?

Do institutionals and insiders have more ownership in IMMX or ANIP?

Do analysts prefer IMMX or ANIP?

Summary

How does Immix Biopharma compare to Lakefront Biotherapeutics American Depositary Shares?

Which has more volatility and risk, LKFT or IMMX?

Do analysts rate LKFT or IMMX?

Which has higher valuation and earnings, LKFT or IMMX?

Does the media favor LKFT or IMMX?

Is LKFT or IMMX more profitable?

Do insiders and institutionals believe in LKFT or IMMX?

Summary

How does Immix Biopharma compare to Bausch Health Cos?

Does the media prefer BHC or IMMX?

Which has higher earnings and valuation, BHC or IMMX?

Is BHC or IMMX more profitable?

Do institutionals and insiders have more ownership in BHC or IMMX?

Which has more risk and volatility, BHC or IMMX?

Do analysts recommend BHC or IMMX?

Summary

How does Immix Biopharma compare to Rapport Therapeutics?

Does the media favor IMMX or RAPP?

Do analysts recommend IMMX or RAPP?

Which has more volatility and risk, IMMX or RAPP?

Do insiders and institutionals hold more shares of IMMX or RAPP?

Is IMMX or RAPP more profitable?

Which has better earnings & valuation, IMMX or RAPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools